Top

Gepubliceerd in:

28-02-2019 | Original Article

d-Cycloserine-Augmented Behavior Therapy for Body Dysmorphic Disorder: A Preliminary Efficacy Trial

Auteurs: Hilary Weingarden, Suraj S. Mothi, Ilana Ladis, Susanne Hoeppner, Hannah E. Reese, Kiara Timpano, Jedidiah Siev, Jessica Rasmussen, Jennifer Ragan, Darin D. Dougherty, Sabine Wilhelm

Gepubliceerd in: Cognitive Therapy and Research | Uitgave 5/2019

Abstract

Cognitive behavioral therapy (CBT) is the leading psychotherapeutic treatment for body dysmorphic disorder (BDD), yet not all patients improve. To address the treatment response gap, CBT may be augmented with cognitive enhancers such as d-cycloserine (DCS). DCS-augmented behavior therapy has been tested with mixed results in related disorders. To initially test whether DCS may augment CBT for BDD, we conducted the first preliminary efficacy trial of DCS versus placebo-augmented CBT for BDD, via a randomized, double-blind study. We analyzed data using mixed-effects models in a modified intent-to-treat sample (N = 26). Over 10 weeks of treatment, primary (BDD severity) and secondary (insight, depression) outcomes improved significantly across both conditions, but there were no significant group differences in response. Exploratory analysis revealed that BDD-related distress, specifically, reduced significantly more in the DCS condition compared to placebo. This is the first study testing DCS-augmented CBT for BDD. Implications, limitations, and future directions are discussed.

Trial registry: ClinicalTrials.gov Identifier NCT00842309

vorige artikel Dynamic Changes in a Desire to Escape from Interpersonal Adversity: A Fluid Experimental Assessment of the Interpersonal Theory of Suicide

volgende artikel Reactivation and Evaluation of Mastery Experiences Promotes Exposure Benefit in Height Phobia

American Psychiatric Association [APA]. (2013). Diagnostic and statistical manual of mental disorders (5th ed.). Washington, DC: American Psychiatric Association.CrossRef

Andersson, E., Hedman, E., Enander, J., Djurfeldt, D. R., Ljótsson, B., Cervenka, S., Isung, J., Svanborg, C., Mataix-Cols, D., Kaldo, V., Andersson, G., Lindefors, N., & Rück, C. (2015). d-Cycloserine vs placebo as adjunct to cognitive behavioral therapy for obsessive-compulsive disorder and interaction with antidepressants: A randomized clinical trial. JAMA Psychiatry, 72, 659–667. https://doi.org/10.1001/jamapsychiatry.2015.0546.CrossRefPubMed

Beck, A. T., Steer, R. A., & Brown, G. K. (1996). Beck depression inventory-second edition: manual. San Antonio, TX: Psychological Corporation.

Buhlmann, U., Glaesmer, H., Mewes, R., Fama, J. M., Wilhelm, S., Brähler, E., & Rief, W. (2010). Updates on the prevalence of body dysmorphic disorder: A population-based survey. Psychiatry Research, 178, 171–175. https://doi.org/10.1016/j.psychres.2009.05.002.CrossRefPubMed

Chasson, G. S., Buhlmann, U., Tolin, D. F., Rao, S. R., Reese, H. E., Rowley, T., Welsh, K., & Wilhelm, S. (2010). Need for speed: Evaluating slopes of OCD recovery in behavior therapy enhanced with d-cycloserine. Behaviour Research and Therapy, 48, 675–679. https://doi.org/10.1016/j.brat.2010.03.007.CrossRefPubMed

Davis, M., & Myers, K. M. (2002). The role of glutamate and gamma-aminobutyric acid in fear extinction: Clinical implications for exposure therapy. Biological Psychiatry, 52, 998–1007.CrossRefPubMed

de Leeuw, A. S., van Megen, H. J. G. M., Kahn, R. S., & Westenberg, H. G. M. (2017). d-Cycloserine addition to exposure sessions in the treatment of patients with obsessive-compulsive disorder. European Psychiatry, 40, 38–44. https://doi.org/10.1016/j.eurpsy.2016.06.011.CrossRefPubMed

Eisen, J. L., Phillips, K. A., Baer, L., Beer, D. A., Atala, K. D., & Rasmussen, S. A. (1998). The Brown Assessment of Beliefs Scale: Reliability and validity. American Journal of Psychiatry. 155. 102–108. https://doi.org/10.1176/ajp.155.1.102..CrossRefPubMed

Fang, A., & Hofmann, S. G. (2010). Relationship between social anxiety disorder and body dysmorphic disorder. Clinical Psychology Review, 30, 1040–1048. https://doi.org/10.1016/j.cpr.2010.08.001.CrossRefPubMedPubMedCentral

Farrell, L. J., Waters, A. M., Boschen, M. J., Hattingh, L., McConnell, H., Milliner, E. L., Collings, N., Zimmer-Gembeck, M., Shelton, D., Ollendick, T. H., Testa, C., & Storch, E. A. (2013). Difficult-to-treat pediatric obsessive-compulsive disorder: Feasibility and preliminary results of a randomized pilot trial of d-cycloserine-augmented behavior therapy. Depression and Anxiety, 30, 723–731. https://doi.org/10.1002/da.22132.CrossRefPubMed

First, M. B., Spitzer, R. L., Gibbon, M., & Williams, J. B. (2002). The structured clinical interview for the DSM-IV-TR Axis I disorders (SCID-I/P). (Research version, patient ed.). New York: Biometrics Research.

Guastella, A. J., Richardson, R., Lovibond, P. F., Rapee, R. M., Gaston, J. E., Mitchell, P., & Dadds, M. R. (2008). A randomized controlled trial of d-cycloserine enhancement of exposure therapy for social anxiety disorder. Biological Psychiatry, 63, 544–549. https://doi.org/10.1016/j.biopsych.2007.11.011.CrossRefPubMed

Gueorguieva, R., & Krystal, J. H. (2004). Move over ANOVA: Progress in analyzing repeated-measures data and its reflection in papers published in the Archives of General Psychiatry. Archives of General Psychiatry, 61, 310–317. https://doi.org/10.1001/archpsyc.61.3.310.CrossRefPubMed

Hedges, L., & Olkin, I. (1985). Statistical methods for meta-analysis. New York: Academic Press.

Hedges, L. V. (1981). Distribution theory for Glass’s estimator of effect size and related estimators. Journal of Educational and Behavioral Statistics, 6, 107–128. https://doi.org/10.3102/10769986006002107.CrossRef

Hofmann, S. G. (2016). Schrödinger’s cat and d-cycloserine to augment exposure therapy-both are alive and dead. JAMA Psychiatry, 73, 771–772. https://doi.org/10.1001/jamapsychiatry.2016.1132.CrossRefPubMed

Hofmann, S. G., Carpenter, J. K., Otto, M. W., Rosenfield, D., Smits, J. A. J., & Pollack, M. H. (2015). Dose timing of d-cycloserine to augment cognitive behavioral therapy for social anxiety: Study design and rationale. Contemporary Clinical Trials, 43, 223–230. https://doi.org/10.1016/j.cct.2015.06.015.CrossRefPubMedPubMedCentral

Hofmann, S. G., Meuret, A. E., Smits, J. A., Simon, N. M., Pollack, M. H., Eisenmenger, K., Shiekh, M., & Otto, M. W. (2006). Augmentation of exposure therapy with d-cycloserine for social anxiety disorder. Archives of General Psychiatry, 63, 298. https://doi.org/10.1001/archpsyc.63.3.298.CrossRefPubMed

Hofmann, S. G., Otto, M. W., Pollack, M. H., & Smits, J. A. (2015). d-Cycloserine augmentation of cognitive behavioral therapy for anxiety disorders: An update. Current Psychiatry Reports, 17, 532. https://doi.org/10.1007/s11920-014-0532-2.CrossRefPubMed

Hofmann, S. G., Smits, J. A., Rosenfield, D., Simon, N. M., Otto, M. W., Meuret, A. E., Fang, A., Tart, C., & Pollack, M. H. (2013). d-Cycloserine as an augmentation strategy with cognitive-behavioral therapy for social anxiety disorder. America Journal of Psychiatry, 170, 751–758. https://doi.org/10.1176/appi.ajp.2013.12070974.CrossRef

Koran, L. M., Abujaoude, E., Large, M. D., & Serpe, R. T. (2008). The prevalence of body dysmorphic disorder in the United States adult population. CNS Spectrums, 13, 316–322.CrossRefPubMed

Kushner, M. G., Kim, S. W., Donahue, C., Thuras, P., Adson, D., Kotlyar, M., McCabe, J., Peterson, J., & Foa, E. B. (2007). D-Cycloserine augmented exposure therapy for obsessive-compulsive disorder. Biological Psychiatry, 62, 835–838. https://doi.org/10.1016/j.biopsych.2006.12.020.CrossRefPubMed

Mataix-Cols, D., Fernández de la Cruz, L., Monzani, B., Rosenfield, D., Andersson, E., Pérez-Vigil, A., & Rück, C. (2017). D-Cycloserine augmentation of exposure-based cognitive behavior therapy for anxiety, obsessive-compulsive, and posttraumatic stress disorders: A systematic review and meta-analysis of individual participant data. JAMA Psychiatry, 74, 501–510. https://doi.org/10.1001/jamapsychiatry.2016.3955.CrossRefPubMed

Mataix-Cols, D., Turner, C., Monzani, B., Isomura, K., Murphy, C., Krebs, G., & Heyman, I. (2014). Cognitive-behavioural therapy with post-session D-cycloserine augmentation for paediatric obsessive-compulsive disorder: Pilot randomised controlled trial. British Journal of Psychiatry, 204, 77–78. https://doi.org/10.1192/bjp.bp.113.126284.CrossRefPubMed

Otto, M. W., Kredlow, M. A., Smits, J. A. J., Hofmann, S. G., Tolin, D. F., de Kleine, R. A., van Minnen, A., Evins, A. E., & Pollack, M. H. (2016). Enhancement of psychosocial treatment with d-cycloserine: Models, moderators, and future directions. Biological Psychiatry, 80, 274–283. https://doi.org/10.1016/j.biopsych.2015.09.007.CrossRefPubMed

Phillips, K. A., Hart, A. S., & Menard, W. (2014). Psychometric evaluation of the Yale-Brown Obsessive-Compulsive Scale Modified for Body Dysmorphic Disorder (BDD-YBOCS). Journal of Obsessive Compulsive and Related Disorders, 3, 205–208.CrossRef

Phillips, K. A., Hart, A. S., Menard, W., & Eisen, J. L. (2013). Psychometric evaluation of the Brown Assessment of Beliefs Scale in body dysmorphic disorder. Journal of Nervous and Mental Disease, 201, 640–643. https://doi.org/10.1097/NMD.0b013e3182983041.CrossRefPubMed

Phillips, K. A., Hollander, E., Rasmussen, S. A., & Aronowitz, B. R. (1997). A severity rating scale for body dysmorphic disorder: Development, reliability, and validity of a modified version of the Yale-Brown Obsessive Compulsive Scale. Psychopharmacology Bulletin, 33, 17–22.PubMed

Rief, W., Buhlmann, U., Wilhelm, S., Borkenhagen, A., & Brahler, E. (2006). The prevalence of body dysmorphic disorder: A population-based survey. Psychological Medicine, 36, 877–885. https://doi.org/10.1017/S0033291706007264.CrossRefPubMed

SAS Institute, Inc. (2016). The SAS system for Windows, version 9.4. Cary, NC: SAS Institute, Inc.

Schieber, K., Kollei, I., de Zwaan, M., & Martin, A. (2015). Classification of body dysmorphic disorder—What is the advantage of the new DSM-5 criteria? Journal of Psychosomatic Research, 78, 223–227. https://doi.org/10.1016/j.jpsychores.2015.01.002.CrossRefPubMed

Smits, J. A. J., Rosenfield, D., Otto, M. W., Marques, L., Davis, M. L., Meuret, A. E., Simon, N. M., Pollack, M. H., & Hofmann, S. G. (2013). d-Cycloserine enhancement of exposure therapy for social anxiety disorder depends on the success of exposure sessions. Journal of Psychiatric Research, 47, 1455–1461. https://doi.org/10.1016/j.jpsychires.2013.06.020.CrossRefPubMedPubMedCentral

Storch, E. A., Merlo, L. J., Bengtson, M., Murphy, T. K., Lewis, M. H., Yang, M. C., Jacob, M. L., Larson, M., Hirch, A., Fernandez, M., Geffken, G. R., & Goodman, W. K. (2007). D-Cycloserine does not enhance exposure-response prevention therapy in obsessive-compulsive disorder. International Clinical Psychopharmacology, 22, 230–237. https://doi.org/10.1097/YIC.0b013e32819f8480.CrossRefPubMed

Storch, E. A., Murphy, T. K., Goodman, W. K., Geffken, G. R., Lewin, A. B., Henin, A., Micco, J. A., Sprich, S., Wilhelm, S., Bengston, M., & Geller, D. A. (2010). A preliminary study of D-cycloserine augmentation of cognitive-nehavioral therapy in pediatric obsessive-compulsive disorder. Biological Psychiatry, 68, 1073–1076. https://doi.org/10.1016/j.biopsych.2010.07.015.CrossRefPubMedPubMedCentral

Storch, E. A., Wilhelm, S., Sprich, S., Henin, A., Micco, J., Small, B. J., McGuire, J., Mutch, P. J., Lewin, A. B., Murphy, T. K., & Geller, D. A. (2016). Efficacy of augmentation of cognitive behavior therapy with weight-adjusted d-cycloserine vs placebo in pediatric obsessive-compulsive disorder: A randomized clinical trial. JAMA Psychiatry, 73, 779–788. https://doi.org/10.1001/jamapsychiatry.2016.1128.CrossRefPubMedPubMedCentral

Veale, D., Anson, M., Miles, S., Pieta, M., Costa, A., & Ellison, N. (2014). Efficacy of cognitive behaviour therapy versus anxiety management for body dysmorphic disorder: A randomised controlled trial. Psychotherapy and Psychosomatics, 83, 341–353. https://doi.org/10.1159/000360740.CrossRefPubMed

Veale, D., & Neziroglu, F. (2010). Body dysmorphic disorder: A treatment manual. West Sussex: Wiley-Blackwell.CrossRef

Walker, D. L., Ressler, K. J., Lu, K. T., & Davis, M. (2002). Facilitation of conditioned fear extinction by systemic administration or intra-amygdala infusions of D-cycloserine as assessed with fear-potentiated startle in rats. The Journal of Neuroscience, 22, 2343–2351.CrossRefPubMed

Wilhelm, S., Buhlmann, U., Tolin, D. F., Meunier, S. A., Pearlson, G. D., Reese, H. E., Cannistraro, P., Jenike, M. A., & Rauch, S. L. (2008). Augmentation of behavior therapy with D-cycloserine for obsessive-compulsive disorder. American Journal of Psychiatry, 165, 335–341. https://doi.org/10.1176/appi.ajp.2007.07050776. (quiz 409).CrossRefPubMed

Wilhelm, S., Phillips, K. A., Didie, E., Buhlmann, U., Greenberg, J. L., Fama, J. M., Keshaviah, A., & Steketee, G. (2014). Modular cognitive-behavioral therapy for body dysmorphic disorder: A randomized controlled trial. Behavior Therapy, 45, 314–327. https://doi.org/10.1016/j.beth.2013.12.007.CrossRefPubMed

Wilhelm, S., Phillips, K. A., & Steketee, G. (2013). Cognitive-behavioral therapy for body dysmorphic disorder: A treatment manual. New York: Guilford Press.

Titel: d-Cycloserine-Augmented Behavior Therapy for Body Dysmorphic Disorder: A Preliminary Efficacy Trial
Auteurs: Hilary Weingarden
Suraj S. Mothi
Ilana Ladis
Susanne Hoeppner
Hannah E. Reese
Kiara Timpano
Jedidiah Siev
Jessica Rasmussen
Jennifer Ragan
Darin D. Dougherty
Sabine Wilhelm
Publicatiedatum: 28-02-2019
Uitgeverij: Springer US
Gepubliceerd in: Cognitive Therapy and Research / Uitgave 5/2019
Print ISSN: 0147-5916
Elektronisch ISSN: 1573-2819
DOI: https://doi.org/10.1007/s10608-019-10015-0

Andere artikelen Uitgave 5/2019

Reactivation and Evaluation of Mastery Experiences Promotes Exposure Benefit in Height Phobia

Original Article

Depressive Suppression: Effects of Emotion Suppression on Multiple Emotions for Depressed Versus Nondepressed Individuals

Original Article

4/20 Cannabis Use is Greater than Other High-Risk Events: Identification of Psychosocial Factors Related to 4/20 Use

Original Article

Transdiagnostic Mechanisms of Psychopathology in Youth: Executive Functions, Dependent Stress, and Rumination

Original Article

Cognitive Moderation of CBT: Disorder-Specific or Transdiagnostic Predictors of Treatment Response

Original Article

Client Motivation and Engagement in Transdiagnostic Group Cognitive Behavioral Therapy for Anxiety Disorders: Predictors and Outcomes

Original Article

Bohn Stafleu van Loghum

Welkom bij THIM Hogeschool voor Fysiotherapie & Bohn Stafleu van Loghum

Registreer

Login

d-Cycloserine-Augmented Behavior Therapy for Body Dysmorphic Disorder: A Preliminary Efficacy Trial

Abstract

Andere artikelen Uitgave 5/2019

Reactivation and Evaluation of Mastery Experiences Promotes Exposure Benefit in Height Phobia

Depressive Suppression: Effects of Emotion Suppression on Multiple Emotions for Depressed Versus Nondepressed Individuals

4/20 Cannabis Use is Greater than Other High-Risk Events: Identification of Psychosocial Factors Related to 4/20 Use

Transdiagnostic Mechanisms of Psychopathology in Youth: Executive Functions, Dependent Stress, and Rumination

Cognitive Moderation of CBT: Disorder-Specific or Transdiagnostic Predictors of Treatment Response

Client Motivation and Engagement in Transdiagnostic Group Cognitive Behavioral Therapy for Anxiety Disorders: Predictors and Outcomes

Bohn Stafleu van Loghum

Welkom bij THIM Hogeschool voor Fysiotherapie & Bohn Stafleu van Loghum

Registreer

Login

Deel dit onderdeel of sectie (kopieer de link)

Abstract

Log in om toegang te krijgen

Reactivation and Evaluation of Mastery Experiences Promotes Exposure Benefit in Height Phobia

Depressive Suppression: Effects of Emotion Suppression on Multiple Emotions for Depressed Versus Nondepressed Individuals

4/20 Cannabis Use is Greater than Other High-Risk Events: Identification of Psychosocial Factors Related to 4/20 Use

Transdiagnostic Mechanisms of Psychopathology in Youth: Executive Functions, Dependent Stress, and Rumination

Cognitive Moderation of CBT: Disorder-Specific or Transdiagnostic Predictors of Treatment Response

Client Motivation and Engagement in Transdiagnostic Group Cognitive Behavioral Therapy for Anxiety Disorders: Predictors and Outcomes